MMP9 and Peyronie disease: Genes that were upregulated (mean fold change ± SE) in both Dupuytren disease nodules and Peyronie's disease plaques compared with healthy tissue included MMPs (MMP‐2: Dupuytren disease, 29.0 ± 10.0 [n = 9]; Peyronie's disease, 4.7 ± 2.6 [n = 2]; MMP‐9: Peyronie's disease, 50.8 ± 0.8 [n = 2]) and peptide activators of MMPs, thymosins (TMSβ‐10: Dupuytren disease, 5.9 ± 2.6 [n = 9]; Peyronie's disease, 5.5 ± 1.3 [n = 5]; TMSβ‐4: Dupuytren disease, 5.9 ± 1.5 [n = 8]; and Peyronie's disease, 2.5 ± 0.9 [n = 5]).35